Wells Fargo downgraded Halozyme to Equal Weight from Overweight with a price target of $62, up from $58. The firm sees limited upside after year-to-date outperformance. Further, Wells notes that Street accounts for new launches and new Vyvgart royalty arrangement likely worsens 2027/2029 royalty stepdown issue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO: